{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Venous+Retinal+Branch+Occlusion",
    "query": {
      "condition": "Venous Retinal Branch Occlusion"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 32,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Venous+Retinal+Branch+Occlusion&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T04:31:37.810Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01011374",
      "title": "Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Venous Retinal Branch Occlusion",
        "Central Retinal Vein Occlusion",
        "Retinal Vein Occlusion",
        "Depression"
      ],
      "interventions": [
        {
          "name": "ranibizumab (Lucentis)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Retina Associates of Cleveland, Inc",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2009-11",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2011-03-18",
      "last_synced_at": "2026-07-22T04:31:37.810Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01011374"
    },
    {
      "nct_id": "NCT04120636",
      "title": "Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Macula Edema",
        "Radiation Retinopathy",
        "Branch Retinal Vein Occlusion",
        "Epiretinal Membrane",
        "Central Serous Retinopathy With Pit of Optic Disc",
        "Commotio Retinae",
        "Vitritis"
      ],
      "interventions": [
        {
          "name": "Episcleral Celecoxib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Targeted Therapy Technologies, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2021-03-05",
      "completion_date": "2024-06-30",
      "has_results": false,
      "last_update_posted_date": "2023-11-24",
      "last_synced_at": "2026-07-22T04:31:37.810Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04120636"
    },
    {
      "nct_id": "NCT04120311",
      "title": "Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Macular Edema",
        "Radiation Retinopathy",
        "Branch Retinal Vein Occlusion",
        "Epiretinal Membrane",
        "Central Serous Retinopathy With Pit of Optic Disc",
        "Commotio Retinae",
        "Vitritis"
      ],
      "interventions": [
        {
          "name": "Episcleral Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Targeted Therapy Technologies, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2019-09-01",
      "completion_date": "2024-09-30",
      "has_results": false,
      "last_update_posted_date": "2023-11-24",
      "last_synced_at": "2026-07-22T04:31:37.810Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04120311"
    },
    {
      "nct_id": "NCT01521559",
      "title": "Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Branch Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Macular Laser Photocoagulation",
          "type": "PROCEDURE"
        },
        {
          "name": "Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 183,
      "start_date": "2012-04",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2014-11-13",
      "last_synced_at": "2026-07-22T04:31:37.810Z",
      "location_count": 45,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01521559"
    },
    {
      "nct_id": "NCT00500045",
      "title": "Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Central Retinal Vein Occlusion",
        "Branch Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "nicotinic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Palo Alto Medical Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2007-02",
      "completion_date": "2016-10",
      "has_results": true,
      "last_update_posted_date": "2019-11-13",
      "last_synced_at": "2026-07-22T04:31:37.810Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00500045"
    },
    {
      "nct_id": "NCT07205887",
      "title": "A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration (NVAMD)",
        "Branch Retinal Vein Occlusion (BRVO)"
      ],
      "interventions": [
        {
          "name": "EYE103",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept 2.0 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EyeBiotech Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2025-09-12",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-07-22T04:31:37.810Z",
      "location_count": 49,
      "location_summary": "Scottsdale, Arizona • Glendale, California • Modesto, California + 28 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Modesto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07205887"
    },
    {
      "nct_id": "NCT05127525",
      "title": "EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema",
        "Branch Retinal Vein Occlusion",
        "Glaucoma/Closed Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "IRX-101",
          "type": "DRUG"
        },
        {
          "name": "Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "iRenix Medical, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2021-11-15",
      "completion_date": "2022-01-31",
      "has_results": false,
      "last_update_posted_date": "2022-05-24",
      "last_synced_at": "2026-07-22T04:31:37.810Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05127525"
    },
    {
      "nct_id": "NCT02503540",
      "title": "Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Retinal Vein Occlusion",
        "Diabetic Macular Edema",
        "Branch Retinal Vein Occlusion",
        "Central Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Justis Ehlers",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2015-08-18",
      "completion_date": "2018-02-06",
      "has_results": true,
      "last_update_posted_date": "2021-05-12",
      "last_synced_at": "2026-07-22T04:31:37.810Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02503540"
    },
    {
      "nct_id": "NCT00101764",
      "title": "Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Macular Degeneration",
        "Retinal Vein Occlusion",
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Triamcinolone Acetonide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2005-01-05",
      "completion_date": "2008-05-20",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-07-22T04:31:37.810Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00101764"
    },
    {
      "nct_id": "NCT02390245",
      "title": "Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Glaucoma",
        "Glaucoma Suspect",
        "Diabetic Retinopathy",
        "Ocular Hypertension",
        "Cataract",
        "Branch Retinal Vein Occlusion",
        "Branch Retinal Arterial Occlusion",
        "Central Retinal Vein Occlusion",
        "Central Retinal Artery Occlusion",
        "Epi-retinal Membrane",
        "Macular Degeneration",
        "Drusen",
        "Loss of Vision"
      ],
      "interventions": [
        {
          "name": "Free Eye Screenings",
          "type": "OTHER"
        },
        {
          "name": "Enhanced Intervention",
          "type": "OTHER"
        },
        {
          "name": "Usual Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Wills Eye",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 906,
      "start_date": "2014-09",
      "completion_date": "2020-08",
      "has_results": true,
      "last_update_posted_date": "2022-08-22",
      "last_synced_at": "2026-07-22T04:31:37.810Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02390245"
    }
  ]
}